Form 4: Neurocrine Biosciences Director Exercises Options and Sells Shares Under 10b5-1 Plan

Gary A. Lyons, a director of Neurocrine Biosciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 13, 2024, Gary A. Lyons, a director of Neurocrine Biosciences Inc., exercised non-qualified stock options to acquire 11,570 shares of common stock at a price of $42.76 per share.
• On the same day, Lyons sold 11,570 shares of common stock at a weighted average price of $150.4278 per share, with individual sales prices ranging from $150.00 to $151.30.
• The sale was executed under a Rule 10b5-1 trading plan adopted on February 13, 2024.
• Following these transactions, Lyons directly owns 119,047 shares of Neurocrine Biosciences common stock and indirectly owns 113,064 shares through a revocable living trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions by a company director. There is no indication of positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions. Directors often use Rule 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The exercise of options and subsequent sale is a common practice for executives to monetize their equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a director.
• The sale of shares could slightly increase the stock's float.

Key Dates